ABEONA THERAPEUTICS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ABEONA THERAPEUTICS INC. (ABEO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.37M, a 19.05% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.96M, a 9.48% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.56M, a 30.90% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.69M, a 49.06% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.78M, a 62.63% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.63M, a 39.01% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.77M, a 56.28% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.05M, a 65.78% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.37M 10-Q · filed 2026-08-13 | $6.33M 10-Q · filed 2026-08-13 | $8.88M derived: sum of 3 quarters · filed 2026-08-13 | $11.57M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $2.96M 10-Q · filed 2026-05-13 | $5.52M derived: sum of 2 quarters · filed 2026-05-13 | $8.21M derived: sum of 3 quarters · filed 2026-05-13 | $11.04M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.25M derived: sum of 2 quarters · filed 2026-03-17 | $8.08M derived: sum of 3 quarters · filed 2026-08-13 | $10.78M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $2.69M 10-Q · filed 2025-11-12 | $5.52M derived: sum of 2 quarters · filed 2026-08-13 | $8.22M 10-Q · filed 2025-11-12 | $10.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $2.83M 10-Q · filed 2026-08-13 | $5.53M 10-Q · filed 2026-08-13 | $7.49M derived: sum of 3 quarters · filed 2026-08-13 | $9.29M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.70M 10-Q · filed 2026-05-13 | $4.66M derived: sum of 2 quarters · filed 2026-05-13 | $6.46M derived: sum of 3 quarters · filed 2026-05-13 | $7.78M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.76M derived: sum of 2 quarters · filed 2026-03-17 | $5.08M derived: sum of 3 quarters · filed 2026-03-17 | $6.63M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | $1.80M 10-Q · filed 2025-11-12 | $3.13M derived: sum of 2 quarters · filed 2025-11-12 | $4.67M 10-Q · filed 2025-11-12 | $6.19M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.32M 10-Q · filed 2025-08-14 | $2.87M 10-Q · filed 2025-08-14 | $4.38M derived: sum of 3 quarters · filed 2025-08-14 | $5.94M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.55M 10-Q · filed 2025-05-15 | $3.06M derived: sum of 2 quarters · filed 2025-05-15 | $4.62M derived: sum of 3 quarters · filed 2025-05-15 | $5.54M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.07M derived: sum of 2 quarters · filed 2025-03-20 | $4.00M derived: sum of 3 quarters · filed 2025-03-20 | $4.77M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $1.56M 10-Q · filed 2024-11-14 | $2.48M derived: sum of 2 quarters · filed 2024-11-14 | $3.25M 10-Q · filed 2024-11-14 | $4.09M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $927.00K 10-Q · filed 2024-08-12 | $1.70M 10-Q · filed 2024-08-12 | $2.53M derived: sum of 3 quarters · filed 2024-08-12 | $3.16M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $770.00K 10-Q · filed 2024-05-15 | $1.60M derived: sum of 2 quarters · filed 2024-05-15 | $2.23M derived: sum of 3 quarters · filed 2024-05-15 | $2.96M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $833.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.47M derived: sum of 2 quarters · filed 2024-03-18 | $2.19M derived: sum of 3 quarters · filed 2024-03-18 | $3.05M 10-K · filed 2024-03-18 | ||||
| 2022-09-30 | $632.00K 10-Q · filed 2023-11-13 | $1.36M derived: sum of 2 quarters · filed 2023-11-13 | $2.22M 10-Q · filed 2023-11-13 | $4.22M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $724.00K 10-Q · filed 2023-08-08 | $1.59M 10-Q · filed 2023-08-08 | $3.59M derived: sum of 3 quarters · filed 2023-08-08 | $6.12M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $862.00K 10-Q · filed 2023-05-11 | $2.86M derived: sum of 2 quarters · filed 2023-05-11 | $5.40M derived: sum of 3 quarters · filed 2023-05-11 | $7.83M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.54M derived: sum of 2 quarters · filed 2023-03-29 | $6.97M derived: sum of 3 quarters · filed 2023-03-29 | $8.92M 10-K · filed 2023-03-29 | $5.25M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $2.54M 10-Q · filed 2022-11-14 | $1.39M 10-Q · filed 2021-11-15 | $4.96M derived: sum of 2 quarters · filed 2022-11-14 | $6.92M 10-Q · filed 2022-11-14 | $3.80M 10-Q · filed 2021-11-15 | $8.69M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $2.43M 10-Q · filed 2022-08-11 | $1.33M 10-Q · filed 2021-07-28 | $4.38M 10-Q · filed 2022-08-11 | $2.41M 10-Q · filed 2021-07-28 | $6.15M derived: sum of 3 quarters · filed 2022-08-11 | $7.40M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $1.95M 10-Q · filed 2022-05-13 | $1.08M 10-Q · filed 2021-05-17 | $3.72M derived: sum of 2 quarters · filed 2022-05-13 | $4.97M derived: sum of 3 quarters · filed 2022-05-13 | $6.55M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.02M derived: sum of 2 quarters · filed 2022-03-31 | $4.60M derived: sum of 3 quarters · filed 2022-03-31 | $5.85M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $1.25M 10-Q · filed 2021-11-15 | $2.83M derived: sum of 2 quarters · filed 2021-11-15 | $4.08M 10-Q · filed 2021-11-15 | $5.81M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $1.58M 10-Q · filed 2021-07-28 | $2.83M 10-Q · filed 2021-07-28 | $4.57M derived: sum of 3 quarters · filed 2021-07-28 | $6.39M derived: sum of 4 quarters · filed 2021-07-28 | ||||
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-17 | $2.99M derived: sum of 2 quarters · filed 2021-05-17 | $4.81M derived: sum of 3 quarters · filed 2021-05-17 | $6.49M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $3.56M derived: sum of 2 quarters · filed 2021-03-24 | $5.24M derived: sum of 3 quarters · filed 2021-03-24 | $7.34M 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | $1.83M 10-Q · filed 2020-11-09 | $3.50M derived: sum of 2 quarters · filed 2020-11-09 | $5.61M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $1.68M 10-Q · filed 2020-08-10 | $3.78M derived: sum of 2 quarters · filed 2020-08-10 | ||||||
| 2019-03-31 | $2.10M 10-Q · filed 2020-08-10 | |||||||
| 2018-12-31 | $8.18M 10-K · filed 2020-03-16 | |||||||
| 2018-09-30 | $2.50M 10-Q · filed 2019-11-12 | $5.17M derived: sum of 2 quarters · filed 2019-11-12 | $7.07M derived: sum of 3 quarters · filed 2019-11-12 | |||||
| 2018-06-30 | $2.67M 10-Q · filed 2019-11-12 | $4.57M derived: sum of 2 quarters · filed 2019-11-12 | ||||||
| 2018-03-31 | $1.90M 10-Q · filed 2019-11-12 | |||||||
| 2017-12-31 | $4.64M 10-K · filed 2020-03-16 | |||||||
| 2017-09-30 | $792.00K 10-Q · filed 2017-11-14 | $2.04M derived: sum of 2 quarters · filed 2017-11-14 | $3.53M derived: sum of 3 quarters · filed 2017-11-14 | |||||
| 2017-06-30 | $1.24M 10-Q · filed 2017-11-14 | $2.73M derived: sum of 2 quarters · filed 2017-11-14 | ||||||
| 2017-03-31 | $1.49M 10-Q · filed 2017-11-14 | |||||||
| 2016-12-31 | $4.83M 10-K · filed 2019-03-18 | |||||||
| 2016-09-30 | $917.00K 10-Q · filed 2016-11-14 | $2.30M derived: sum of 2 quarters · filed 2016-11-14 | $3.89M derived: sum of 3 quarters · filed 2016-11-14 | |||||
| 2016-06-30 | $1.39M 10-Q · filed 2016-11-14 | $2.98M derived: sum of 2 quarters · filed 2016-11-14 | ||||||
| 2016-03-31 | $1.59M 10-Q · filed 2016-11-14 | |||||||
| 2015-12-31 | $4.37M 10-K · filed 2017-03-30 | |||||||
| 2015-09-30 | $1.45M 10-Q · filed 2015-11-16 | $2.36M derived: sum of 2 quarters · filed 2015-11-16 | $2.58M derived: sum of 3 quarters · filed 2015-11-16 | |||||
| 2015-06-30 | $904.00K 10-Q · filed 2015-11-16 | $1.13M derived: sum of 2 quarters · filed 2015-11-16 | ||||||
| 2015-03-31 | $224.00K 10-Q · filed 2015-11-16 | |||||||
| 2014-12-31 | $1.30M 10-K · filed 2016-03-30 | |||||||
| 2013-12-31 | $439.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |